Revista y Edición

AHEAD OF PRINT

Volumen 69 (2022): Edición 2 (August 2022)

Volumen 69 (2022): Edición s1 (July 2022)

Volumen 69 (2022): Edición 1 (January 2022)

Volumen 68 (2021): Edición 2 (December 2021)

Volumen 68 (2021): Edición 1 (January 2021)

Volumen 67 (2020): Edición 2 (May 2020)

Volumen 67 (2020): Edición 1 (January 2020)

Volumen 66 (2019): Edición 2 (November 2019)

Volumen 66 (2019): Edición 1 (June 2019)

Volumen 65 (2018): Edición 2 (November 2018)

Volumen 65 (2018): Edición 1 (June 2018)

Volumen 64 (2017): Edición 2 (November 2017)

Volumen 64 (2017): Edición 1 (September 2017)

Volumen 63 (2016): Edición s12 (December 2016)

Volumen 63 (2016): Edición 2 (December 2016)

Volumen 63 (2016): Edición 1 (September 2016)

Volumen 62 (2015): Edición s10 (September 2015)

Volumen 62 (2015): Edición s9 (June 2015)

Volumen 62 (2015): Edición 2 (December 2015)

Volumen 62 (2015): Edición 1 (June 2015)

Volumen 61 (2014): Edición 2 (December 2014)

Volumen 61 (2014): Edición 1 (August 2014)

Volumen 60 (2013): Edición Supplementum-VIII (March 2013)
Rare disease day in Slovakia, Europlan national conference

Volumen 60 (2013): Edición 2 (December 2013)

Volumen 60 (2013): Edición 1 (June 2013)

Volumen 59 (2012): Edición Supplement-VII (February 2012)
Conference abstracts, Rare disease day, conference 29.2.2012, First Slovak conference about rare diseases

Volumen 59 (2012): Edición Supplement-VI (January 2012)
Clinical Pharmacy in the Slovak Republic, dedicated to the associated professor Lívia Magulová, PhD.

Volumen 59 (2012): Edición 2 (November 2012)

Volumen 59 (2012): Edición 1 (June 2012)

Volumen 58 (2011): Edición 1 (January 2011)

Detalles de la revista
Formato
Revista
eISSN
2453-6725
Publicado por primera vez
25 Nov 2011
Periodo de publicación
2 veces al año
Idiomas
Inglés

Buscar

Volumen 69 (2022): Edición s1 (July 2022)

Detalles de la revista
Formato
Revista
eISSN
2453-6725
Publicado por primera vez
25 Nov 2011
Periodo de publicación
2 veces al año
Idiomas
Inglés

Buscar

6 Artículos
access type Acceso abierto

Presentations

Publicado en línea: 22 Jun 2022
Páginas: 1 - 28

Resumen

access type Acceso abierto

Posters

Publicado en línea: 18 Jun 2022
Páginas: 29 - 78

Resumen

access type Acceso abierto

Secondary prevention of patients with ischaemic stroke after recanalization treatment

Publicado en línea: 13 Jul 2022
Páginas: 79 - 81

Resumen

Abstract

We performed a retrospective analysis of 100 patients with ischaemic stroke. All patients underwent intravenous thrombolysis in the acute care setting (avg. 2.8 hours, max 4.5 hours) and 10 of them also underwent mechanical thrombectomy. For 20% of the patients, the stroke was fatal. Door to needle time was 38.46 minutes. Although changes in antithrombotic treatment were introduced due to strokes, there was no significant difference in National Institute of Health Stroke Scale scores between the patients who were on antithrombotic treatment and those who were on no antithrombotic treatment.

Palabras clave

  • ischaemic stroke
  • secondary prevention
  • antiplatelet therapy
  • anticoagulant therapy
  • intravenous thrombolysis
access type Acceso abierto

Endocrine changes in women with a medically indicated abortion: the study design

Publicado en línea: 25 Jun 2022
Páginas: 82 - 83

Resumen

Abstract

A strongly psychosocially demanding situation in the life of a woman is the option of medically indicated abortion. Here we present the design of an ongoing study aiming to examine the stressfulness of life events related to medically indicated abortions by measuring cortisol concentrations in the participants’ hair and saliva. Pilot results show high salivary cortisol concentrations in the majority of the women one day before induced abortion. In half of the group, two months after the abortion, hair cortisol concentrations were higher in comparison to cumulative values from two months before. There were no changes in the second half.

Palabras clave

  • medically indicated abortion
  • cortisol
  • stress
  • clinical trial
access type Acceso abierto

Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

Publicado en línea: 18 Jun 2022
Páginas: 84 - 86

Resumen

Abstract

Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8 %). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.

Palabras clave

  • Immune checkpoint inhibitors
  • immunotherapy
  • adverse effect
  • autoimmunity
access type Acceso abierto

Optimisation of flow cytometric detection of intracellular SLAMF receptor-associated adaptor proteins SAP and EAT-2

Publicado en línea: 18 Jun 2022
Páginas: 87 - 89

Resumen

Abstract

SAP and EAT-2 are intracellular adaptor proteins that link SLAMF receptors to downstream intracellular signalling pathways. Their expression and functions vary among different types of hematopoietic cells. The roles of SAP and EAT-2 in haematological malignancies are poorly understood. Here, we attempted to optimise a method for the detection of intracellular SAP and EAT-2 by flow cytometry. We found that using PerFix EXPOSE kit for cell fixation and permeabilization ensures optimal results in terms of staining intensity and signal-to-noise ratio.

Palabras clave

  • SLAMF receptors
  • SAP
  • EAT-2
  • lymphocytes
  • flow cytometry
6 Artículos
access type Acceso abierto

Presentations

Publicado en línea: 22 Jun 2022
Páginas: 1 - 28

Resumen

access type Acceso abierto

Posters

Publicado en línea: 18 Jun 2022
Páginas: 29 - 78

Resumen

access type Acceso abierto

Secondary prevention of patients with ischaemic stroke after recanalization treatment

Publicado en línea: 13 Jul 2022
Páginas: 79 - 81

Resumen

Abstract

We performed a retrospective analysis of 100 patients with ischaemic stroke. All patients underwent intravenous thrombolysis in the acute care setting (avg. 2.8 hours, max 4.5 hours) and 10 of them also underwent mechanical thrombectomy. For 20% of the patients, the stroke was fatal. Door to needle time was 38.46 minutes. Although changes in antithrombotic treatment were introduced due to strokes, there was no significant difference in National Institute of Health Stroke Scale scores between the patients who were on antithrombotic treatment and those who were on no antithrombotic treatment.

Palabras clave

  • ischaemic stroke
  • secondary prevention
  • antiplatelet therapy
  • anticoagulant therapy
  • intravenous thrombolysis
access type Acceso abierto

Endocrine changes in women with a medically indicated abortion: the study design

Publicado en línea: 25 Jun 2022
Páginas: 82 - 83

Resumen

Abstract

A strongly psychosocially demanding situation in the life of a woman is the option of medically indicated abortion. Here we present the design of an ongoing study aiming to examine the stressfulness of life events related to medically indicated abortions by measuring cortisol concentrations in the participants’ hair and saliva. Pilot results show high salivary cortisol concentrations in the majority of the women one day before induced abortion. In half of the group, two months after the abortion, hair cortisol concentrations were higher in comparison to cumulative values from two months before. There were no changes in the second half.

Palabras clave

  • medically indicated abortion
  • cortisol
  • stress
  • clinical trial
access type Acceso abierto

Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

Publicado en línea: 18 Jun 2022
Páginas: 84 - 86

Resumen

Abstract

Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8 %). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.

Palabras clave

  • Immune checkpoint inhibitors
  • immunotherapy
  • adverse effect
  • autoimmunity
access type Acceso abierto

Optimisation of flow cytometric detection of intracellular SLAMF receptor-associated adaptor proteins SAP and EAT-2

Publicado en línea: 18 Jun 2022
Páginas: 87 - 89

Resumen

Abstract

SAP and EAT-2 are intracellular adaptor proteins that link SLAMF receptors to downstream intracellular signalling pathways. Their expression and functions vary among different types of hematopoietic cells. The roles of SAP and EAT-2 in haematological malignancies are poorly understood. Here, we attempted to optimise a method for the detection of intracellular SAP and EAT-2 by flow cytometry. We found that using PerFix EXPOSE kit for cell fixation and permeabilization ensures optimal results in terms of staining intensity and signal-to-noise ratio.

Palabras clave

  • SLAMF receptors
  • SAP
  • EAT-2
  • lymphocytes
  • flow cytometry

Planifique su conferencia remota con Sciendo